SteadyMed reels in losses with Q4 earnings

Shares in SteadyMed (NSDQ:STDY) rose yesterday after the pharmaceutical company reported its 4th quarter results.

The San Ramon, Calif.-based company posted losses of -$2.4 million, or -12¢ per share, on sales of $400,000 for the 3 months ended Dec. 31, for bottom-line growth of 63.1% on sales loss of -25.6% compared with the same period last year.

“2016 was a year of important progress for SteadyMed, which saw our company significantly advance the development of its lead product candidate, Trevyent for the treatment of PAH. These are exciting times for SteadyMed as we look forward to learning of our IPR ruling in April and submit our NDA for Trevyent to the FDA at the end of the 2nd quarter,” president & CEO Jonathan Rigby said in prepared remarks.

Get the full story at our sister site, Drug Delivery Business News.

The post SteadyMed reels in losses with Q4 earnings appeared first on MassDevice.

from MassDevice http://ift.tt/2nk4HEn